Cerenis Therapeutics SA, a privately-held French pharmaceutical company developing treatments for cardiovascular and metabolic diseases, has in-licensed intellectual property supporting an investigational new treatment of aortic valve stenosis based on high-density lipoprotein therapy. This technology is based on the findings of a study led by Jean-Claude Tardif, at the Montreal Heart Institute Research Centre in Canada. AVS is characterized by a narrowing of the aortic valve and can cause a potentially dangerous imbalance in blood pressure and results in over 50,000 aortic valve replacement surgeries each year in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze